NCT06679153View on ClinicalTrials.gov

A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

December 29, 2024

Study Completion Date

December 29, 2024

Conditions
Anterior Uveitis
Interventions
DRUG

VVN461 Ophthalmic Solution 1.0%

VVN461 Ophthalmic Solution, 1.0%, for up to 28 days

DRUG

VVN461 Ophthalmic Solution 0.5%

VVN461 Ophthalmic Solution, 0.5%, for up to 28 days

DRUG

Prednisolone acetate

Prednisolone acetate, 1%, for up to 28 days

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

All Listed Sponsors
lead

VivaVision Biotech, Inc

INDUSTRY

NCT06679153 - A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis | Biotech Hunter | Biotech Hunter